Wetin na di men kayn kansa na yu bɔdi? (Types of Breast Cancer) Lɛ wi ɔndastand am simpul wan

I at fɔ put insay wɔd di fred ɛn shɔk we yu kin fil we yu kam fɔ no se yu gɛt bɔdi kansa. Yu gɛt bɔku kwɛstyɔn dɛn na yu maynd. Na nɔmal tin fɔ gɛt kwɛstyɔn dɛn lɛk, "Wetin mek dis apin to mi?", "Wetin a de du naw?", "Dɛn kin mɛn dis?". Insai dis joyn, a de trai to explein tins simpul and fo langwej we yu go andastan. Fɔ no gud gud wan us kayn kansa yu gɛt tan lɛk fɔ ɔndastand di ɛnimi bifo yu bigin fɛt. Dat na di fɔs ɛn impɔtant tin fɔ pik di tritmɛnt we go fayn fɔ yu.

Hɔmɔn Risɛptɔ-Pozitiv Brest Kansa

Dis na di kayn kansa we kin kam pan pɔsin in bɔdi. If wi tɔk am roughly, na lɛk 80 pan ɛvri 100 bɔdi kansa kin de insay dis kategori.

So wetin dis "hormone-dependent" min?

Jɔs tink bɔt am. Wi bɔdi, mɔ di uman dɛn bɔdi, gɛt tu ɔmon dɛn we de na di wɔl we dɛn kɔl ɛstrojen ɛn prɔjɛstɛron . dis dεm implεnt fכ nכmal prכsεs dεm na wi bכdi. כltu, sכm kεnsar sεl dεm kin rili "adik" to dεn כmon dεm ya. dat min se, pan di sכfayz fכ dεn kεnsar sεl dεm, sכm sכm "rεsεpכta" כ do dεm de we dεn כmon dεm ya kin kam εn stik to. We di ɛstrojen ɔmon kam ɛn nak na da domɔt de, di kansa sɛl kin gɛt tin fɔ it frɔm am ɛn i kin bigin fɔ gro ɛn sheb. Jɔs lɛk we yu wata plant, i kin gro big.

if yu mεdikal ripot se `ER-positiv` (Estrogen Receptor-Positive), i min se yu kansa sεl dεm de sεnsitiv to di כmon εstrojen. if i se `PR-positiv` (Progesterone Receptor-Positive), i min se i sεnsitiv to di כmon progesterone. If i sɛnsitiv to ɛni wan pan dɛn wan ya, dɛn kin kɔl di kansa ɔmon riseptɔ-pɔzitiv kansa.

Bɔku tɛm, dɛn kin gi ɔmon tɛrapi afta dɛn dɔn ɔpreshɔn, kemotɛrapi, ɔ redyushɔn fɔ mek di kansa nɔ kam bak. dis mεdikal dεm de wok bay we dεn de kכloz di "dכ" dεm na di kεnsar sεl dεm, כ bay we dεn de stכp di bכdi fכ mek εstrojen.

HER2-Pozitiv Brest Kansa

Naw lɛ wi tɔk bɔt ɔda kayn. sכm brεst kεnsar sεl dεm (lεk 20% pan כl di kεnsar dεm) de prodyuz tu mכch wan spεshal protin na dεn sεf we dεn kכl HER2 (Human Epidermal growth factor Receptor 2) .

Tink bɔt HER2 lɛk smɔl ɛntena we de tɛl di kansa sɛl fɔ "grɔw fast, divayd fast." Nɔmal sɛl gɛt sɔm pan dɛn ɛntena dɛn ya nɔmɔ. Bɔt wan HER2-positiv kansa sɛl gɛt bɔku pan dɛn ɛntena dɛn ya. Na dat mek dɛn kayn kansa ya kin mek pɔsin vɛks mɔ .

Bɔt gud nyus de ya bak. wit di advans dεm na sayns, naw "targeted therapies " de we de tכk εn pwεl dεn vεri HER2 antena dεm ya. biכs dεn ya de fכn εn atak כnli di sεl dεm we gεt tu mכch HER2, nכmal sεl dεm de dכn sכmtεm.

Di men ɛn di bɛst mɛrɛsin we dɛn gi fɔ dis na Trastuzumab (Herceptin) . Dis kin ɛp bad bad wan fɔ mek di kansa nɔ kam bak. Bɔt, smɔl risk de fɔ sɔm ifɛkt pan di at ɔr lɔng we yu de tek dis tritmɛnt. Nɔ wɔri bɔt dat , yu dɔktɔ go de chɛk fɔ am ɔltɛm.

"Tripul-Negativ" Brest Kansa

Dis na di tɔd men kayn. bכt 10%-20% pan di brεst kεnsar dεm de fכl insay dis kayn. yu no wetin mek dem kol am "triple-negative" o "triple negative"?

Bikɔs insay dɛn kansa sɛl dɛn ya , .

1. Nɔ εstrojen rεsεpכta (ETU) .

2. Nɔ prɔjɛstɛron riseptɔ (PR).

3. Nכto bכku HER2 protin de.

Bikɔs dɛn kansa sɛl ya nɔ gɛt di tri men target dɛm we wi bin dɔn tɔk bɔt, nɔto ɔmon tɛrapi ɔ HER2-targeted therapies lɛk Herceptin de wok pan dɛm. So fɔ trit dɛn kin tranga smɔl.

Dɛn kin trit dis kayn we mɔ wit ɔpreshɔn, kemotɛrapi, ɛn redyushɔn . Bɔt naw, nyu tritmɛnt dɛn de we spɛshal fɔ dis kayn.

• PARP Inhibitors: Dɛn kin yuz drɔgs lɛk Olaparib (Lynparza) ɛn Talazoparib (Talzenna) fɔ pipul dɛn we gɛt BRCA jin muteshon. Dɛn tin ya kin mek di kansa sɛl dɛn nɔ ebul fɔ mek dɛnsɛf fayn.
• Immunotherapy: Drug dεm lεk Atezolizumab (Tecentriq) de εp fכ fכt kansa sεl dεm bay we wi de yuz wi כwn imyun sεl dεm.

Dis ɔl kin tan lɛk se i kɔmplikt smɔl. Dat na nɔmal tin. Di impɔtant tin na fɔ mɛmba se ilɛk us kayn kansa yu gɛt, tritmɛnt dɛn de tide we fit fɔ am. Yu dɔktɔ ɛn di mɛdikal tim go wok wit yu fɔ mek di bɛst tritmɛnt plan fɔ yu.